EUVIMEDEUVIMED entdecken
Editorial

(Un)intended consequences of mass-prescribing GLP-1s

Luc L Hagenaars, Laura A Schmidt

Science · 2026

DOI: 10.1126/science.ael8715 ↗

Kurz gefasst

Editorial in der Zeitschrift Science, 2026. Verfasst von Luc L Hagenaars und 1 weiteren Autor:innen. Beteiligte Einrichtung: Luc L. Hagenaars is an assistant professor in the Department of Public and Occupational Health, Amsterdam UMC Location, University of Amsterdam, Amst…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Semaglutide.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It is difficult to overstate how much glucagon-like peptide-1 (GLP-1) pharmacotherapies have inundated the public discourse on obesity. An avalanche of scientific papers, news articles, and social media posts debate the efficacy, affordability, and appropriateness of GLP-1 receptor agonists not just for obesity but also skin disease, erectile dysfunction, pregnancy, and addiction. Attempting to cut through the noise, the World Health Organization (WHO) recently published the first-ever global guidelines recommending GLP-1s for the treatment of obesity, while committing to develop a global framework ensuring “fair access” to these medicines for the 1 billion people affected worldwide. Going deeper, the guidelines also advocate for “robust populationlevel policies” to address the root causes of obesity in unhealthy food environments. However, to complicate these efforts, WHO’s recommendations unfold at a time rife with competitive pressures among pharmaceutical companies, food companies vying for the GLP-1 market segment, and wellness companies promoting supplements and telemedicine programs for what is being billed as a GLP-1 lifestyle. This commercial milieu is ripe for unintended consequences that conspire against fair access to these medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsObesitySemaglutideAnti-Obesity AgentsHumansWorld Health OrganizationDrug PrescriptionsPractice Guidelines as Topic

Substanzen

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideAnti-Obesity Agents

Autor:innen und Institutionen

  • Luc L. Hagenaars is an assistant professor in the Department of Public and Occupational Health, Amsterdam UMC Location, University of Amsterdam, Amsterdam, Netherlands.
  • Laura A. Schmidt is a professor at the Philip R. Lee Institute for Health Policy Studies, School of Medicine, University of California San Francisco, San Francisco, CA, USA.

Zitieren

APA

Hagenaars, L. L., & Schmidt, L. A. (2026). (Un)intended consequences of mass-prescribing GLP-1s. Science. https://doi.org/10.1126/science.ael8715

Vancouver

Hagenaars LL, Schmidt LA. (Un)intended consequences of mass-prescribing GLP-1s. Science. 2026. doi:10.1126/science.ael8715

BibTeX
@article{Hagenaars2026,
  author = {Hagenaars, Luc L and Schmidt, Laura A},
  title = {(Un)intended consequences of mass-prescribing GLP-1s},
  journal = {Science},
  year = {2026},
  doi = {10.1126/science.ael8715}
}
Kostenlos starten →